World Allergy Congress 2024
Sep 27 - Sep 29, 2024
- Title: Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Presenter: Marcin Stobiecki, M.D.
Format: Oral (OA013)
Date, time: Friday, September 27, from 7:50-7:58 WEST (2:50-2:58 a.m. EDT) - Title: Long-term efficacy and safety of oral deucrictibant, a bradykinin B2 receptor antagonist, in treatment of hereditary angioedema attacks: Results of the RAPIDe-2 extension study
Presenter: Henriette Farkas, M.D., Ph.D., D.Sc.
Format: Oral (OA014)
Date, time: Friday, September 27, from 8:00-8:08 WEST (3:00-3:08 a.m. EDT) - Title: Prophylactic treatment with oral deucrictibant improves health-related quality of life in patients with hereditary angioedema
Presenter: Marcin Stobiecki, M.D.
Format: Oral (OA015)
Date, time: Friday, September 27, from 8:10-8:18 WEST (3:10-3:18 a.m. EDT)